Rituximab therapy in a patient with low grade B-cell lymphoproliferative disease and concomitant acquired angioedema

Ravdeep Kaur
Aerik Anthony Williams
Catherine Baker Swift
Jason W Caldwell
Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC, USA

Abstract: Acquired angioedema is often associated with significant morbidity. An underlying lymphatic malignancy, autoimmune disorder, adenocarcinoma, or other malignancy may be present. Screening for these disorders should occur in all patients with acquired angioedema as treatment may result in resolution of angioedema.

Keywords: complement, C1-INH deficiency, ecallantide, hemopathy

Introduction

Acquired deficiency of the inhibitor of the first component of human complement (C1-INH) is an extraordinarily rare cause of intermittent episodes of angioedema, with approximately 100 cases reported in published literature.1 Underlying low grade lymphoid hemopathies, in which immediate chemotherapy is typically unwarranted, may be associated with acquired C1-INH deficiency. In such patients, treatment with rituximab (Genentech, Inc., San Francisco, CA, USA) can ameliorate symptoms of angioedema.2,3

Case presentation

A 51-year-old male with a past medical history of chronic obstructive pulmonary disease and depression described a 2-year history of intermittent edema of the hands, feet, genitals, and tongue occurring approximately once per month. He had experienced two episodes of laryngeal edema requiring intubation. He denied any associated urticaria, pruritus, or flushing. He had been managed acutely for these symptoms with epinephrine injection, corticosteroids, and antihistamines with no improvement. His active medications were albuterol and duloxetine. At the time of presentation he was a current smoker with a 15-pack–year history. He was seen in consult in the critical care unit of Wake Forest Baptist Medical Center, Winston-Salem, NC, USA after an episode of laryngeal edema requiring intubation. An undetectable C4 of <5 mg/dL (reference range [ref] 15–70 mg/dL) prompted administration of 30 mg of subcutaneous ecallantide (Dyax Corp, Burlington, MA, USA), which led to rapid resolution of swelling. Further complement assays were consistent with acquired C1-INH deficiency: C1-INH of 5 mg/dL (ref: 21–39 mg/dL), a C1-INH function of 16% (ref: >68%), and undetectable C1q of <3.6 mg/dL (ref: 5–8.6 mg/dL).

Evaluation to ascertain an etiology of acquired angioedema led to the discovery of an increased total number and percentage of B-cells (1,240 cells/µL [ref: 50–870 cells/µL] and 34% [ref: 5%–17%]). In addition, the percentage of T-lymphocytes was low (62.9%...
of urticaria and pruritus, and appears to be largely mediated by bradykinin. Pharmacologic treatment options for acute attacks include C1-INH concentrate, kallikrein inhibitor concentrate, and B2 bradykinin receptor blockade agents.

Chemotherapy for MGUS or B-cell lymphoproliferative disease is not always indicated; however, patients with concomitant acquired C1-INH deficiency may benefit from such treatment. In a patient with acquired angioedema and B-cell lymphoma, Levi et al described cessation of symptoms after treatment with rituximab. A review by Branellec et al describes outcomes of rituximab therapy in seven patients with acquired C1-INH deficiency, five of which had an underlying B-cell lymphoproliferative disease or MGUS. Two of these five patients had no subsequent attacks after treatment.

Certainly the prevalence of acquired angioedema in the setting of low grade B-cell lymphoproliferative disease is low, with only a few case reports published in literature. Trials in which such patients are randomized to a rituximab group or alternative therapy group are impractical. Therefore, case reports are paramount so that practitioners can make management decisions based on a collective experience.

In the above patient with acquired C1-INH deficiency in the setting of low grade B-cell lymphoma, rituximab eradicated symptoms of life threatening angioedema. Therefore, rituximab warrants consideration for patients with recurrent angioedema in the setting of acquired C1-INH deficiency and low grade B-cell lymphoproliferative disease.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**
